Full TIG­IT da­ta from Gilead, Ar­cus show low­er PFS rates than De­cem­ber read­out: #AS­CO23

CHICA­GO — Gilead and Ar­cus un­veiled a fuller snap­shot of a Phase II study test­ing their ex­per­i­men­tal can­cer im­munother­a­py com­bo that showed low­er pro­gres­sion-free sur­vival rates …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER